Journal article icon

Journal article

Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections

Abstract:

he annual incidence of pneumonia has been reported as 13.8/1000 in patients with IBD versus 7.6/1000 in healthy subjects (IRR 1.82; 95% CI: 1.75–1.88) [1]. Vedolizumab (VDZ) is a humanised monoclonal antibody that binds to α4β7 integrin, selectively blocking gut-specific lymphocyte trafficking. Gut selectivity may reduce the infection risk compared with anti-tumour necrosis factor-alpha [anti-TNFα] agents, which cause systemic immunosuppression. Here we describe pneumonia and other respirator...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjx002.792

Authors


More by this author
Institution:
University of Oxford
Department:
Linacre College
Role:
Author
Publisher:
Oxford University Press Publisher's website
Journal:
Journal of Crohn's and Colitis Journal website
Volume:
11
Issue:
S1
Pages:
S421–S422
Publication date:
2017-02-01
DOI:
ISSN:
1873-9946
Pubs id:
pubs:719788
URN:
uri:d86dbdcc-3b70-4aee-aae4-2c127c727be0
UUID:
uuid:d86dbdcc-3b70-4aee-aae4-2c127c727be0
Local pid:
pubs:719788
Paper number:
S1

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP